Jeffrey A Klosterman Optometrist Inc Optometrist Medicare: Not Enrolled in Medicare Practice Location: 101 S Main St, Harrodsburg, KY 40330 Phone: 859-734-3697 Fax: 859-734-3695 |
Dr. Stephanie Johnson, OD Optometrist Medicare: Medicare Enrolled Practice Location: 591 Joseph Drive, Wal-mart Vision Cneter, Harrodsburg, KY 40330 Phone: 859-734-1783 |
Matthew Dugger Eyecare Optometrist Medicare: Medicare Enrolled Practice Location: 1028 N College St Ste 8b, Harrodsburg, KY 40330 Phone: 859-605-2214 Fax: 859-402-2606 |
Dr. Jeffrey A. Klosterman, OD Optometrist Medicare: Medicare Enrolled Practice Location: 125 Collin Drive, Harrodsburg, KY 40330 Phone: 859-734-3697 Fax: 859-734-3695 |
Ms. Tammy Gwyn Hoskins, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 201 S Main St, Harrodsburg, KY 40330 Phone: 859-734-3155 Fax: 859-734-3159 |
Dr. Rebecca Schleter Harris, O.D. Optometrist Medicare: Medicare Enrolled Practice Location: 125 Collin Dr, Harrodsburg, KY 40330 Phone: 859-734-2020 Fax: 859-734-3695 |
Harrodsburg Eye Center Optometrist Medicare: Medicare Enrolled Practice Location: Harrodsburg Eye Center, 201 S Main St, Harrodsburg, KY 40330 Phone: 859-734-3155 |
News Archive
"This clinical trial proves beyond any doubt that inside the artery therapy is the best possible treatment for patients suffering an acute ischemic stroke from a large artery occlusion," according to Donald Frei, MD, Neuro Interventional Surgeon at Swedish Medical Center and Radiology Imaging Associates in Englewood, CO.
Newly discovered molecular differences between small cell lung cancer and nonsmall cell lung cancer have revealed PARP1 and EZH2 as potential therapeutic targets for patients with small cell lung cancer, according to the results of a study published in Cancer Discovery, a journal of the American Association for Cancer Research.
Ryan Gilbert, assistant professor in the Department of Biomedical Engineering at Rensselaer Polytechnic Institute, has won a prestigious Faculty Early Career Development Award (CAREER) from the National Science Foundation (NSF).
Esperance Pharmaceuticals presented its Phase 1 study of EP-100, a novel targeted membrane‐disrupting peptide (tMDP) in advanced solid tumors at the American Society for Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois.
› Verified 7 days ago